Endogenex Raises $50M Extension to Advance Diabetes Treatment Platform

Medtech funding usually lands like a spreadsheet update. Clean, clinical, easy to skim. This one lands more like a signal, sharp and deliberate, aimed straight at a problem most people still misunderstand. Endogenex just pulled in a $50M Series C extension, led by Arboretum Ventures with participation from existing investors, stacking neatly on top of the $88M Series C from June 2024. That brings the total Series C haul to $138M. Not loose change, not experimental curiosity money. This is conviction capital stepping in when the stakes are clinical, regulatory, and very real.

Big respect to CEO Stacey Pugh and the team for navigating a category where hype dies fast and data does all the talking. Clinical-stage medtech is where optimism gets cross-examined, and Endogenex is still standing in the witness box with a clear story.

That story runs through the duodenum, which is not exactly where most people look when they think about type 2 diabetes. Endogenex does. Their ReCET procedure uses pulsed electric fields delivered endoscopically to trigger mucosal regeneration and reset metabolic signaling. Translation without the lab coat: they are going upstream, not downstream, aiming at the biological control center instead of just managing the symptoms after the fact.

And that is where the capital makes sense. You do not raise $138M in a Series C unless 2 things are true. 1, the science has enough signal to keep serious investors at the table. 2, the roadmap is expensive, long, and worth it. This extension is about finishing the pivotal ReCET Clinical Study and pushing through the FDA pathway. No shortcuts, no theatrics, just execution.

Arboretum Ventures stepping in as lead here is not a casual endorsement. This is a firm that understands the difference between a clever device and a category-defining platform. The returning syndicate, including names like Hatteras Venture Partners, Lumira Ventures, Orlando Health Ventures, Intuitive Ventures, Longitude Capital, Mayo Clinic, and Santé Ventures, tells you something even louder. Nobody quietly doubles down in medtech. You either believe, or you are gone.

The business lesson sitting underneath all of this is simple, but not easy. Build something that attacks root cause, anchor it in credible clinical pathways, and surround it with partners who know how to navigate regulatory reality. That is how you earn the right to keep raising when the milestones get harder, not easier.

Endogenex is not selling a device yet. They are selling a future where a single outpatient procedure could shift how we think about metabolic disease. If they land it, this does not just change treatment. It changes expectations.